Navigation Links
DiaTech Oncology and Walter Reed Army Medical Center Establish Pilot to Determine Best Chemotherapy for Cancer Patients
Date:2/8/2011

WASHINGTON, Feb. 8, 2011 /PRNewswire/ -- DiaTech Oncology announced today they have engaged in a pilot with Walter Reed Army Medical Center to determine the best Chemotherapy for Cancer patients. Medical and GYN Oncologists and from Walter Reed have been working with DiaTech Oncology (Nashville, TN) using the MiCK assay for apoptosis in order to give physicians a tool that can predict the best chemotherapy pathway in treating cancer patients. The study will eventually be introduced to other military hospitals and results will be collected on multiple cancers. Previous studies published by DiaTech have demonstrated the MiCK assay can increase the patient's response to chemotherapy, resulting in increased patient survival. In addition, the assay can guide the physician on single vs. combination therapy and when generic vs. proprietary drugs are more effective.  

"To be able to predict the best chemotherapy treatment for cancer patients has been a goal for oncologists for many years and we now have the data that proves this technology works for all cancers. In addition the test can guide a physician on choosing between single drug or combination treatments and whether to use less expensive generic drugs or newer proprietary drugs based on which drugs will give the patient the most effective response," said Dr. Cary Presant, DiaTech Medical Director, and Professor of Clinical Medicine at the University of Southern California Keck School of Medicine.In the MiCK assay, the tumor cells of an individual patient are exposed to multiple doses of several chemotherapeutic drugs either as single drugs or in combinations. A sophisticated algorithm is used to monitor and compute the amounts of apoptosis caused by each of the drugs to establish a drug sensitivity profile of the patient's tumor cells. Knowledge of a patient's drug sensitivity profile allows the treating oncologists to prescribe chemotherapy that would be the most effective against the tumor
'/>"/>

SOURCE DiaTech Oncology
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
2. TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch
3. Sentinel Oncology add ADME From O2h to Their New Extended Contract
4. US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials
5. US Oncology to Report 2010 Third Quarter Operating Results
6. Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
7. Dr. Ramin Mirhashemi, MD of Gynecological Oncology Associates Discusses Uterine Fibroid Treatment with da Vinci Robotic Hysterectomy Surgery
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. Reportlinker Adds Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
10. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
11. Reportlinker Adds Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... ALBANY, New York , May 21, 2013 /PRNewswire/ ... published by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip ... Science Research, IVD Tests) - U.S. Industry Analysis, Size, Share, ... USD 2.4 billion in 2011 and is expected to ... 2018, to reach an estimated value of USD 4.7 ...
(Date:5/21/2013)... 2013 Many have long discussed the ... acne. Recently physicians from Clinical Psychiatry.com readdressed ... the skin, and suggested using hypnotherapy and ... produced from stress that cause acne. , Doctors in ... acne brings about, stress causes changes in the skin ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... 21, 2013  Personal Genome Diagnostics Inc. (PGDx), ... methodologies and expertise in genomic analysis of defined ... collaboration with Blueprint Medicines.  PGDx is an innovator ... alterations in tumors, and Blueprint Medicines is an ... a genetically defined patient population. "This ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3
... Microtest Laboratories,( http://www.microtestlabs.com ) has doubled ... purchase of an additional MicroSeq(R),Microbial Identification System., ... sequence-based system that,enables Microtest technicians to more ... not viable or easily identified., "With ...
... June 3 VIA Pharmaceuticals,(Nasdaq: VIAP ), ... for the treatment of cardiovascular disease, announced today ... officer of VIA, and,James G. Stewart, senior vice ... update at the Seventh Annual Needham & Company,Biotechnology ...
... and ... Agriculture Conference, ROME, June 3 More can be done ... help address the,strong and growing global demand for grain, Mike Gumina, vice ... Nations Food and,Agriculture Organization Conference being held here today., "Improved farming ...
Cached Biology Technology:Microtest Labs Doubles Microbial Identification, Analytical Services 2More Can Be Done Now to Address the Growing Global Demand for Grain 2More Can Be Done Now to Address the Growing Global Demand for Grain 3
(Date:5/21/2013)... Michigan Water Center today awarded 12 research grants, ... and protection efforts. , The two-year grants of ... efforts to track the remediation of harmful algae ... non-native weedy plant invasions; study chromosomal damage in ... restoration activities. , The grants were awarded to ...
(Date:5/21/2013)... decades, scientists have developed many devices that can reopen ... generally effective, each of these treatments has drawbacks, including ... from MIT analyzes the potential usefulness of a new ... drug-releasing stents, but may pose fewer risks. With this ... for only a brief period, during which it releases ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... ,Rewilding with taxon substitutes, the intentional introduction of ... the loss of recently extinct species, is highly controversial, ... In a paper published today in Current ... Sciences and colleagues present the first empirical evidence that ...
... they tell of their former lives, these old bones ... And now, geologists have found, they tell of the ... evolutionary ecology of ancient sirenians--commonly known as sea cows--scientist ... could change the view of climate during the Eocene ...
... you belong to the one-half of the population that frequently ... good for you? Well, according to a study ... a journal of the Association for Psychological Science, there seems ... dietary supplement use and the health status of individuals. Wen-Bin ...
Cached Biology News:Giant tortoises show rewilding can work 2Fossil sirenians give scientists new look at ancient climate 2Are dietary supplements working against you? 2
... Chicken polyclonal to Opsin 1 ( Abpromise ... Synthetic peptide: YEDSTHASIFTYT, corresponding to amino acids ... synthetic peptide corresponding to amino acids 18/30 of ... used as immunogen. Entrez Gene ...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Wnt-1 (G-19)...
Biology Products: